Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year Low at $111.11

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hit a new 52-week low on Friday . The stock traded as low as $111.11 and last traded at $111.26, with a volume of 245497 shares changing hands. The stock had previously closed at $113.49.

Analysts Set New Price Targets

JAZZ has been the subject of several recent research reports. Robert W. Baird initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. Needham & Company LLC reiterated a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Finally, Barclays cut their price objective on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Price Performance

The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $6.97 billion, a PE ratio of 18.07, a PEG ratio of 1.57 and a beta of 0.59. The company has a 50-day moving average of $121.21 and a 200 day moving average of $123.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rise Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter. Cape Investment Advisory Inc. lifted its stake in shares of Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 292 shares during the last quarter. ST Germain D J Co. Inc. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $40,000. Covestor Ltd lifted its stake in shares of Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after purchasing an additional 345 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 119 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.